FUROSEMIDE

Search structure


Trade Names:	FUROSEMIDE LASIX
Synonyms:	Aluzine 20 Aluzine 40 Aluzine 500 Aquamed Disal Diuresal Dryptal Froop Frumax Frumil Frusemide Frusetic Frusid Frusol Furosemide Furosemidum Hydroled Lasix Lasix ret LB-502 Logirene Marsemide Mirfat NSC-269420 Oedemex Rusyde Tenkofruse
Status:	Approved (1966)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	C03CA01
UNII:	7LXU5N7ZO5


InChI Key	ZZUFCTLCJUWOSV-UHFFFAOYSA-N
Smile	NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
InChI	InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

Property Name	Value	Unit	Method
log P (octanol-water)	2.03	-	EXP
Henry's Law Constant	3.94E-16	atm-m3/mole	EST
Atmospheric OH Rate Constant	1.12E-10	cm3/molecule-sec	EST
Melting Point	295	deg C	EXP
Water Solubility	73.1	mg/L	EXP
Vapor Pressure	3.23E-10	mm Hg	EST

Action	Mechanism of Action	Reference
INHIBITOR	Sodium-(potassium)-chloride cotransporter 2 inhibitor	DOI DailyMed Wikipedia Wikipedia

	Primary Target
Kidney-specific Na-K-Cl symporter

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Lyase	-	-	-	245	-
Enzyme Oxidoreductase	-	3760	-	-	21
Enzyme Transferase	-	12700	-	-	-
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Carboxylic acid receptor Kynurenic acid receptor	6200-11200	-	-	3270	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	22-90
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	-	12
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC47 family of multidrug and toxin extrusion transporters	-	-	-	-	7
Unclassified protein	-	53460	-	2285	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
Heart Failure	4	D006333	ClinicalTrials
Lung Diseases	3	D008171	ClinicalTrials
Coronary Disease	3	D003327	ClinicalTrials
Renal Insufficiency	3	D051437	ClinicalTrials
Warts	3	D014860	ClinicalTrials
Myocardial Infarction	3	D009203	ClinicalTrials
Atherosclerosis	3	D050197	ClinicalTrials
Tachypnea	3	D059246	ClinicalTrials
Hypercholesterolemia	3	D006937	ClinicalTrials
Pre-Eclampsia	3	D011225	ClinicalTrials
Pulmonary Embolism	3	D011655	ClinicalTrials
Bronchiolitis	3	D001988	ClinicalTrials
Diabetes Mellitus, Type 2	3	D003924	ClinicalTrials
Essential Hypertension	3	D000075222	ClinicalTrials
Kidney Diseases	3	D007674	ClinicalTrials
Renal Insufficiency, Chronic	2	D051436	ClinicalTrials
Keratosis, Actinic	2	D055623	ClinicalTrials
Acute Kidney Injury	2	D058186	ClinicalTrials
Bronchopulmonary Dysplasia	2	D001997	ClinicalTrials
Hypertension, Pregnancy-Induced	2	D046110	ClinicalTrials
Acute Lung Injury	2	D055371	ClinicalTrials
Nasal Polyps	2	D009298	ClinicalTrials
Neoplasms	2	D009369	ClinicalTrials
Dyspnea	1	D004417	ClinicalTrials
Diabetes Mellitus	1	D003920	ClinicalTrials
Leukemia	1	D007938	ClinicalTrials
Schizophrenia	1	D012559	ClinicalTrials
Edema	1	D004487	ClinicalTrials
Leukemia, Myeloid, Acute	1	D015470	ClinicalTrials
Premature Birth	0	D047928	ClinicalTrials

System Organ Classification (SOC)

	Relative Frequency (%)
Cardiac disorders	10.96
General disorders and administration site conditions	10.77
Metabolism and nutrition disorders	10.76
Nervous system disorders	8.07
Renal and urinary disorders	7.38
Vascular disorders	7.36
Investigations	6.98
Respiratory, thoracic and mediastinal disorders	6.12
Injury, poisoning and procedural complications	4.92
Gastrointestinal disorders	4.74
Skin and subcutaneous tissue disorders	4.07
Psychiatric disorders	3.52
Musculoskeletal and connective tissue disorders	3.22
Infections and infestations	2.47

CONTENTS


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70